Christoph B. Olivier

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Axel Bauer, Michael Schreinlechner, Nikolay Sappler et al. · The Lancet Respiratory Medicine · 2021 · 105 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes

Philipp Diehl, Christoph B. Olivier, Christoph Halscheid et al. · Basic Research in Cardiology · 2009 · 66 citations

Medicine, Hematology, Pharmacology +12

P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells

Patrick M. Siegel, Laura Sander, Alba Fricke et al. · Scientific Reports · 2021 · 64 citations · Full text

Medicine, Cardiology, Pharmacology +17

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Barco, Davide Voci, Ulrike Held et al. · The Lancet Haematology · 2022 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease

Christoph B. Olivier, Hillary Mulder, William R. Hiatt et al. · JAMA Cardiology · 2018 · 44 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17